Cingulate, Inc. (CING)
5.34
+0.15
(+2.89%)
USD |
NASDAQ |
Sep 09, 10:55
Cingulate Total Liabilities (Quarterly) : 9.599M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.599M |
| March 31, 2026 | 12.00M |
| December 31, 2025 | 12.56M |
| September 30, 2025 | 7.045M |
| June 30, 2025 | 7.956M |
| March 31, 2025 | 6.539M |
| December 31, 2024 | 7.409M |
| September 30, 2024 | 1.542M |
| June 30, 2024 | 2.043M |
| Date | Value |
|---|---|
| March 31, 2024 | 2.278M |
| December 31, 2023 | 10.36M |
| September 30, 2023 | 5.967M |
| June 30, 2023 | 11.33M |
| March 31, 2023 | 7.081M |
| December 31, 2022 | 7.523M |
| September 30, 2022 | 7.010M |
| June 30, 2022 | 1.619M |
| March 31, 2022 | 2.414M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 896.90M |
| Corcept Therapeutics, Inc. | 182.93M |
| Veru, Inc. | 8.651M |
| Johnson & Johnson | 116.09B |
| Eli Lilly & Co. | 108.40B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 33.07M |
| Shareholders Equity (Quarterly) | 23.47M |
| Debt to Equity Ratio | 0.2681 |
| Current Ratio | 3.50 |
| Net Debt Paydown Yield | -0.32% |